Literature DB >> 30553863

LncRNAs in ovarian cancer.

Jin-Yan Wang1, Ai-Qing Lu2, Li-Juan Chen3.   

Abstract

Ovarian cancer is one of the most common gynecologic malignancies and has a poor prognosis. Recently, long noncoding RNAs (lncRNAs) have been identified as key regulators of cancer development. Studies have shown that the dysregulation of lncRNAs is frequently observed in ovarian cancer and greatly contributes to malignant phenotypical changes. In this review, we provide perspectives on the involvement of lncRNAs in the proliferation, apoptosis, cell cycle, migration, invasion, metastasis and drug resistance of ovarian cancer based on recent discoveries. Then, we discuss the role of lncRNAs in predicting the prognosis of ovarian cancer. Finally, we provide insight into the potential of lncRNAs for evaluating the diagnosis and prognosis of ovarian cancer.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Apoptosis; Diagnosis; LncRNAs; Metastasis; Ovarian cancer; Proliferation

Mesh：

Substances：

Year:  2018        PMID： 30553863     DOI： 10.1016/j.cca.2018.12.013

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN： 0009-8981            Impact factor:   3.786


  37 in total

Review 1.  The role of IGF2BP2, an m6A reader gene, in human metabolic diseases and cancers.

Authors:  Jinyan Wang; Lijuan Chen; Ping Qiang
Journal:  Cancer Cell Int       Date:  2021-02-10       Impact factor: 5.722

2.  The Role of Long Non-Coding RNA CCAT1 and SNHG14 in Activation of Some Protein-Coding Genes Associated with the Development of Ovarian Cancer.

Authors:  O I Brovkina; I V Pronina; A M Burdennyy; L A Uroshlev; E A Filippova; M V Fridman; T P Kazubskaya; K I Zhordania; V I Loginov; N E Kushlinskii; E A Braga
Journal:  Bull Exp Biol Med       Date:  2022-05-02       Impact factor: 0.804

3.  Long non-coding RNA ACTA2-AS1 inhibits the cisplatin resistance of non-small cell lung cancer cells through inhibiting autophagy by suppressing TSC2.

Authors:  XueHui Liu; XuFeng Zhang; ShuZhang Du
Journal:  Cell Cycle       Date:  2022-01-05       Impact factor: 4.534

4.  An Integrative Analysis Revealing ZFHX4-AS1 as a Novel Prognostic Biomarker Correlated with Immune Infiltrates in Ovarian Cancer.

Authors:  Changchang Huang; Hongyin Cui; Xiaolin Lang; Fen Zhao
Journal:  J Immunol Res       Date:  2022-06-26       Impact factor: 4.493

5.  LncRNA PART1 Stimulates the Development of Ovarian Cancer by Up-regulating RACGAP1 and RRM2.

Authors:  Hui Li; Yuansheng Lei; Shuangxue Li; Feng Li; Jieyun Lei
Journal:  Reprod Sci       Date:  2022-05-12       Impact factor: 2.924

6.  Identification of aberrantly expressed long non-coding RNAs in ovarian high-grade serous carcinoma cells.

Authors:  Kengo Nakashima; Shun Sato; Isao Tamura; Maki Hayashi-Okada; Tetsuro Tamehisa; Takuya Kajimura; Kotaro Sueoka; Norihiro Sugino
Journal:  Reprod Med Biol       Date:  2020-05-28

Review 7.  Long Non-Coding RNAs in the Cell Fate Determination of Neoplastic Thymic Epithelial Cells.

Authors:  Alessia Iaiza; Claudia Tito; Federica Ganci; Andrea Sacconi; Enzo Gallo; Silvia Masciarelli; Giulia Fontemaggi; Alessandro Fatica; Enrico Melis; Vincenzo Petrozza; Federico Venuta; Mirella Marino; Giovanni Blandino; Francesco Fazi
Journal:  Front Immunol       Date:  2022-04-22       Impact factor: 8.786

8.  Long non-coding RNA TTTY15 silencing inhibits gastric cancer progression by sponging microRNA-98-5p to down-regulate cyclin D2 expression.

Authors:  Xigang Wen; Wenling Han; Chao Liu
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

9.  A novel ferroptosis related gene signature is associated with prognosis in patients with ovarian serous cystadenocarcinoma.

Authors:  Zhixiang Yu; Haiyan He; Yanan Chen; Qiuhe Ji; Min Sun
Journal:  Sci Rep       Date:  2021-06-01       Impact factor: 4.379

10.  Screening and prognostic value of potential biomarkers for ovarian cancer.

Authors:  Huiqin Li; Ming Li; Chunhui Tang; Liang Xu
Journal:  Ann Transl Med       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.